CVS Test For Detailers 12 October 2011

44 Questions | Total Attempts: 66

SettingsSettingsSettings
CVS Test For Detailers 12 October 2011 - Quiz

Testing knowledge about Losartan and Losartan Co market and cycle 4's market strategy.


Questions and Answers
  • 1. 
    Which product is currently market leader in total ARB/HCTZ market?  
    • A. 

      Fortzaar

    • B. 

      Co-Diovan

    • C. 

      Co-Tareg

    • D. 

      Atacand Plus

    • E. 

      Co-Pritor

  • 2. 
    How big is the combined Losartan/HCTZ market?  
    • A. 

      R20m

    • B. 

      R23,5m

    • C. 

      R19,4m

    • D. 

      R33,5m

  • 3. 
    Which ARB/HCTZ product is the fastest growing product in the ARB/HCTZ market?  
    • A. 

      Co-Diovan

    • B. 

      Fortzaar

    • C. 

      Co-Tareg

    • D. 

      Atacand Plus

    • E. 

      Co-Pritor

  • 4. 
    What percentage of the Losartan/HCTZ market is still held by the originators?  
    • A. 

      50%

    • B. 

      84%

    • C. 

      73%

    • D. 

      96%

    • E. 

      100%

  • 5. 
    Name the first losartan/HCTZ generic
    • A. 

      Fortzaar

    • B. 

      Sartoc

    • C. 

      Lozaan Co

    • D. 

      Co-Pritor

  • 6. 
    Who manufactures the first losartan/HCTZ generic?
    • A. 

      MSD

    • B. 

      Accord

    • C. 

      Aspen

    • D. 

      Sandoz

    • E. 

      Winthrop

  • 7. 
    The main shortcoming of the first losartan/HCTZ was that it was presented in 50/25 mg strength.
    • A. 

      True

    • B. 

      False

  • 8. 
    Name the Akacia losartan/HCTZ generic  
    • A. 

      Lozaan Co

    • B. 

      Losaar Plus

    • C. 

      Fortzaar

    • D. 

      Co-Pritor

  • 9. 
    Name the Ranbaxy losartan/HCTZ generic
    • A. 

      Fortzaar

    • B. 

      Lohype Plus

    • C. 

      Lozaan Co

    • D. 

      Losaar Plus

  • 10. 
    Which losartan/HCTZ strength is the biggest selling SKU? ........./.........mg
    • A. 

      100/25mg

    • B. 

      50/12,5mg

    • C. 

      50/25mg

    • D. 

      80/12,5mg

  • 11. 
    Name the other or competitor losartan/HCTZ generic brand that also has a plain losartan range
    • A. 

      Cipla- Losartan

    • B. 

      Atacand

    • C. 

      Lozaan

    • D. 

      Sartoc

    • E. 

      None of that is mentioned here

    • F. 

      Zartan

  • 12. 
    One feature that is unique to losartan, is that it is particularly helpful to patients who suffer from gout, because it  reduces the mineral acid levels in the body  
    • A. 

      True

    • B. 

      False

  • 13. 
    The type of hypertension that is often seen in elderly patients and is characterized by a large difference between systolic and diastolic blood pressure is called isolated diastolic hypertension.
    • A. 

      True

    • B. 

      False

  • 14. 
    What combination therapy would be a similar but more affordable option from Pharma Dynamics for doctors wishing to prescribe Exforge? Answer:
    • Zartan Co and Amloc / PD Amlodipene
    • A. 

      True

    • B. 

      False

  • 15. 
    The maximum cost saving % between ZARTAN CO and the most affordable telmisartan/HCTZ combination is 32%?
    • A. 

      True

    • B. 

      False

  • 16. 
    Name the product that is market leader in the plain losartan market .
    • A. 

      Cozaar

    • B. 

      Cipla-Losartan

    • C. 

      Zartan

    • D. 

      Diovan

    • E. 

      Spec-Losartan

  • 17. 
    How many patients overall were recruited in the CONFIDENCE study?
    • A. 

      666

    • B. 

      3800

    • C. 

      8300

    • D. 

      1300

    • E. 

      Non of the above

  • 18. 
    In which year was The CONFIDENCE study published in the American Journal of Cardiovascular Drugs?
    • A. 

      2008

    • B. 

      2009

    • C. 

      2010

    • D. 

      2011

  • 19. 
    Which of the following subpopulations were NOT monitored in the CONFIDENCE study?
    • A. 

      Diabetic population

    • B. 

      Metabolic syndrome population

    • C. 

      Asian population

    • D. 

      Severe hypertensive population

  • 20. 
    The authors of the CONFIDENCE study concluded the following
    • A. 

      Perindopril 4-8 mg/day is a dose dependant, effective, and well tolerated antihypertensive treatment

    • B. 

      Perindopril 8 mg significantly lowered BP in severely hypertensive patients

    • C. 

      Uptitration to the optimum dose of perindopril may be considered as an effective approach for the management of hypertension, and conferring the benefits of outcome studies

    • D. 

      All of the above

  • 21. 
    In the CONFIDENCE study, 193 of the severely hypertensive patients were titrated up to perindopril 8mg. What was the BP lowering observed after 12 weeks?
    • A. 

      10.1/5.4 mmHg

    • B. 

      18.9/9.7 mmHg

    • C. 

      23.1/9.0 mmHg

    • D. 

      37.6/15.3 mmHg

  • 22. 
    Perindopril tert-butylamine 8 mg and perindopril arginine 10 mg are both equivalent to the following quantity of active base
    • A. 

      6.7 mg

    • B. 

      7.6 mg

    • C. 

      8.0 mg

    • D. 

      10.0 mg

  • 23. 
    The AUC ratio for perindoprilat from perindopril tert-butylamine 8 mg and perindopril arginine 10 mg was found to be?
    • A. 

      80%

    • B. 

      90%

    • C. 

      69.3%

    • D. 

      100%

  • 24. 
    Perindopril tert-butylamine 8 mg and perindopril arginine 10 mg were found to be
    • A. 

      Therapeutically equivalent in terms of BP lowering

    • B. 

      Interchangable

    • C. 

      Substitutable

    • D. 

      All of the above

  • 25. 
    What is the IMS MAT Rand value of the perindopril plain market?
    • A. 

      R13 million

    • B. 

      R65 million

    • C. 

      R100 million

    • D. 

      R130 million

Back to Top Back to top